Exelixis
EXEL
#1659
Rank
$10.35 B
Marketcap
$36.25
Share price
1.26%
Change (1 day)
72.62%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : $0.19 Billion USD

According to Exelixis's latest financial reports the company's total debt is $0.19 Billion USD. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31$0.18 B-0.12%
2022-12-31$0.19 B270.9%
2021-12-31$51.27 M4.45%
2020-12-31$49.08 M2.24%
2019-12-31$48.01 M221.88%
2018-12-31$14.91 M-0.15%
2017-12-31$14.93 M-92.1%
2016-12-31$0.18 B-54.75%
2015-12-31$0.41 B17.08%
2014-12-31$0.35 B2.8%
2013-12-31$0.34 B3.43%
2012-12-31$0.33 B84.96%
2011-12-31$0.18 B-12.92%
2010-12-31$0.20 B161.83%
2009-12-31$79.61 M-32.34%
2008-12-31$0.11 B-3.16%
2007-12-31$0.12 B-0.11%
2006-12-31$0.12 B-18.27%
2005-12-31$0.14 B1.01%
2004-12-31$0.14 B32.65%
2003-12-31$0.11 B50.25%
2002-12-31$73.93 M51.06%
2001-12-31$48.94 M227.38%
2000-12-31$14.95 M12.41%
1999-12-31$13.3 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
$21.49 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
$25.46 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
$38.13 B 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
$51.40 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
$60.39 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
$35.75 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
$66.61 B 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.55 M-98.17%๐Ÿ‡บ๐Ÿ‡ธ USA
$38.68 M-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA